Future studies, like the SURPASS-CVOT study (NCT04255433), will assess the cardiovascular (CV) safety and efficacy of tirzepatide against dulaglutide (1.5 mg) in people with established coronary heart disease (ASCVD) and type 2 diabetes
"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN 2)"
[1] [2] Key eligibility criteria include a BMI of 35 kg/m or above with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in specific circumstances
Older refrigerators, mini-fridges, and units with frequent door openings can drift outside the safe range without any external indication
Quick Read: Ellie MD Tirzepatide Cost Tirzepatide is a GLP-1 + GIP receptor agonist, meaning it works on two pathways to support appetite control, blood sugar regulation, and reduction in cravings